Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Medivir (MVIR-B) Ser B NPV

Sell:10.18 SEK Buy:10.20 SEK Change: 0.20 SEK (1.93%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:10.18 SEK
Buy:10.20 SEK
Change: 0.20 SEK (1.93%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:10.18 SEK
Buy:10.20 SEK
Change: 0.20 SEK (1.93%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.

Contact details

Lunastigen 7
+46 (8) 54683100

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
578.54 million SEK
Shares in issue:
55.74 million
Stockholm Stock Exchange
Swedish Krona

Key personnel

  • Uli Hacksell
    Chairman of the Board
  • Magnus Christensen
    Chief Financial Officer
  • Christina Herder
    Executive Vice President Strategic Business Development
  • Fredrik Oberg
    Chief Scientific Officer
  • Malene Jensen
    Vice President - Clinical Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.